Information Provided By:
Fly News Breaks for October 15, 2019
Oct 15, 2019 | 09:20 EDT
Baird analyst Brian Skorney raised his price target to $162 from $105 following news its omaveloxolone hit the primary endpoint in MOXle, a place controlled study in Friedreich's ataxia. The study was a major surprise and may now push towards blockbuster status. Skorney reiterated his Outperform rating on Reata Pharmaceuticals shares.
News For RETA From the Last 2 Days
There are no results for your query RETA